Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinical and pathological characteristics in HER2-positive early breast cancer according to TGFBI promoter methylation levels

From: Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Characteristics %
N = 10
p value*
n Median (p25–p75)
Age 10 −0.383* 0.275*1
Menopause   0.151*2
 Premenopausal 5 32.13 (24.58–35.86)  
 Postmenopausal 5 14.58 (−0.68–25.77)
ER   0.089*2
 Negative 2 2.85 (−3.57–9.28)  
 Positive 8 28.50 (19.58–34.00)
HER2 status  
 FISH 0  
 IHC+ 10 25.18 (9.28–32.13)  
Histological grade  
 Grade 1–2 10 25.18 (9.28–32.13)  
 Grade 3 0  
Clinical stage   0.804*3
 IIB 2 16.15 (−3.57–25.86)  
 IIIA 2 19.58 (14.58–24.58)
 IIIB 6 28.50 (9.28–32.13)
Pathological response  
 No response 1 9.28  
 Partial response 9 25.77 (14.58–32.13)  
Percentage of tumor shrinkage** 10 0.029 0.957*1
Miller & Payne   1.000*2
 G2 1 0.68  
 G3 2 22.57 (9.28–35.86)
 G4 7 25.77 (19.58–31.68)
Type of surgery   0.267*2
 Lumpectomy 2 10.51 (−3.57–24.58)  
 Mastectomy 8 28.50 (11.93–34.00)
  1. *1Spearman correlation
  2. *2Mann-Whitney test
  3. *3Kruskal-Wallis test